A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
- Status
- COMPLETED
- Phase
- PHASE2
Related studies linked through entity extraction aliases.